Search results
Results from the WOW.Com Content Network
(S,S)-(+)-Ethambutol is powerful and selective antitubercular drug.It is a typical example of an old drug that was introduced for clinical use in its unichiral form. . Ethambutol contains two constitutionally symmetrical chiral centers in its structure and exists in three stereoisomeric forms, the enantiomeric pair (+)-(S,S)- and (−)-(R,R)-ethambutol, along with the achiral stereoisomer called m
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
Typical symptoms of active TB are chronic cough with blood-containing mucus, fever, night sweats, and weight loss. [1] Infection of other organs can cause a wide range of symptoms. [8] Tuberculosis is spread from one person to the next through the air when people who have active TB in their lungs cough, spit, speak, or sneeze.
Ethambutol/isoniazid is a fixed-dose combination medication used to treat tuberculosis. [1] It is a fixed dose combination of ethambutol and isoniazid. [1] It is used along with other antituberculosis medication. [1] It is taken by mouth. [1] Side effects are those of the underlying medications. [1]
An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics (drugs used to relieve pain). Equianalgesic charts are used for calculation of an equivalent dose (a dose which would offer an equal amount of analgesia) between different analgesics. [1]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Ethionamide is an antibiotic used to treat tuberculosis. [2] Specifically it is used, along with other antituberculosis medications, to treat active multidrug-resistant tuberculosis. [2]
Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company.It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors). [1]